Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Comparison of 68Ga‐PSMA PET/CT and mp‐MRI in regard to local staging for prostate cancer with histopathological results: A retrospective study

Comparison of 68Ga‐PSMA PET/CT and mp‐MRI in regard to local staging for prostate cancer with... INTRODUCTIONThe multiparametric prostate magnetic resonance imaging (mp‐MRI) system combines multiple MRI sequences to diagnose or stage clinically significant prostate cancer. With advancements in technology, mp‐MRI has emerged as a viable method to localize prostate cancer, which can be a cornerstone for active surveillance and focal treatments.1Prostate‐specific membrane antigen is a type‐II membrane protein with folate hydrolase activity produced by prostatic epithelium2 and overexpressed on the membrane of most PCa cells.3 68Ga‐labeled PSMA inhibitors target the PSMA cell surface protein to reveal prostate cancer cells. 68Ga‐PSMA PET/CT can localize prostate cancer with the sensitivity and specificity of 41.5% and 90.9%, respectively.4mp‐MRI is strongly recommended by the European Association of Urology Guidelines for the decision‐making of first and repeat prostate biopsies.4 mp‐MRI has also become an option for targeted prostate biopsies with a high success rate for detection of the intraprostatic index tumor localization (sensitivity: 95% and specificity: 35% for ISUP grade ≥ 3).5 PSMA has also been studied for targeted prostate biopsy in a single study.6 However, 68Ga‐PSMA PET/CT is more likely to be used for clinical staging of prostate cancer with 33%–92% sensitivity and 82%–100% specificity.4To our knowledge, there is limited evidence comparing mp‐MRI and 68Ga‐PSMA PET/CT in regard to locating http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Prostate Wiley

Comparison of 68Ga‐PSMA PET/CT and mp‐MRI in regard to local staging for prostate cancer with histopathological results: A retrospective study

Download PDF
7 pages

Loading next page...
 
/lp/wiley/comparison-of-68ga-psma-pet-ct-and-mp-mri-in-regard-to-local-staging-0LgrhVYQnM

References (17)

Publisher
Wiley
Copyright
© 2022 Wiley Periodicals LLC.
ISSN
0270-4137
eISSN
1097-0045
DOI
10.1002/pros.24420
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONThe multiparametric prostate magnetic resonance imaging (mp‐MRI) system combines multiple MRI sequences to diagnose or stage clinically significant prostate cancer. With advancements in technology, mp‐MRI has emerged as a viable method to localize prostate cancer, which can be a cornerstone for active surveillance and focal treatments.1Prostate‐specific membrane antigen is a type‐II membrane protein with folate hydrolase activity produced by prostatic epithelium2 and overexpressed on the membrane of most PCa cells.3 68Ga‐labeled PSMA inhibitors target the PSMA cell surface protein to reveal prostate cancer cells. 68Ga‐PSMA PET/CT can localize prostate cancer with the sensitivity and specificity of 41.5% and 90.9%, respectively.4mp‐MRI is strongly recommended by the European Association of Urology Guidelines for the decision‐making of first and repeat prostate biopsies.4 mp‐MRI has also become an option for targeted prostate biopsies with a high success rate for detection of the intraprostatic index tumor localization (sensitivity: 95% and specificity: 35% for ISUP grade ≥ 3).5 PSMA has also been studied for targeted prostate biopsy in a single study.6 However, 68Ga‐PSMA PET/CT is more likely to be used for clinical staging of prostate cancer with 33%–92% sensitivity and 82%–100% specificity.4To our knowledge, there is limited evidence comparing mp‐MRI and 68Ga‐PSMA PET/CT in regard to locating

Journal

The Prostate – Wiley

Published: Nov 1, 2022

Keywords: lesion analysis; multiparametric MRI; prostate cancer; prostate mapping; PSMA PET CT

There are no references for this article.